Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Future of Outsourcing: Exploring the Gig Economy - 2Czech Republic's new premier: No money for Ukraine
- 3The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- 4South African radio presenter among five charged over Russia recruitment plot
- 55 Wellbeing Applications Assist You With remaining Fit
- Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- Figure out How to Pick a Crematorium: Key Contemplations.
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- Building an Individual Brand: Illustrations from Powerhouses
- Pick Your Favored kind of sandwich
